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Although the exposure assessment of chemicals of emerging concern (CECs) has taken a decisive step
forward through advances in (bio)informatics, statistics, and the development of highly sophisticated
analytical instruments, the lack of standardisation and harmonisation of analytical workflows and
method performance assessment for suspect and non-target screening hampers the interpretation of
results, their comparability and thus, its transmission to policymakers. To date, unlike in other research
fields such as forensics or food analysis, there is a lack of guidelines for non-target analysis in human risk
assessment and quality assurance and quality control (QA/QC) protocols. Moreover, the majority of ef-
forts have been focused on the development and implementation of QA/QC actions for data acquisition,
data analysis and mining, largely neglecting the sample preparation necessary for determination of CECs
by suspect and non-target screening methods.
In this article, we propose a set of QA/QC measures that covers sampling, sample preparation and data
acquisition, as an aspect of work conducted within the European Biomonitoring for Europe initiative
(HBM4EU). These measures include the use of standardised terminology and the implementation of
dedicated QA/QC actions in each stage of the analytical process. Moreover, a framework for the analytical
performance assessment has been developed for the first time for the identification of CECs in human
samples by suspect and non-target approaches. Adoption of the actions proposed here for the identifi-
cation of CECs in human matrices can significantly improve the comparability of reported results and
contribute to the (challenging) Exposome research field.
© 2021 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).rpen.be (N. Caballero-Casero), Adrian.Covaci@uantwerpen.be (A. Covaci).
ier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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During 2018, more than 300 million tonnes of chemicals were
consumed in the 28 member states of the European Union (EU),
from which 200 million tonnes are known to be hazardous to
health [1]. This extensive use of chemicals results in increased
exposure of the European population to potentially harmful
chemicals, which have been linked with, among other, cancer,
reproductive problems, and adverse effects on the endocrine sys-
tem [2]. In 2012, the World Health Organization (WHO) estimated
1.4 million annual deaths in Europe linked to environmental
pollution [3]. In this context, the EU has adopted appropriate leg-
islative measures as the European Regulation on Registration,
Evaluation, Authorisation and Restriction of Chemicals (REACH) [4],
the Stockholm convention [5], the Rotterdam Convention on the
Prior Informed Consent Procedure for Certain Hazardous Chemicals
and Pesticides in International Trade [6] and the Minamata
Convention [7] which are a significant step forward in the protec-
tion of human health and the environment to commercialised
chemicals. However, the current European legislation does not
cover all the chemicals neither their possible generation of trans-
formation products in the environment and their release from
multiple sources.
The Exposome concept introduced by C.P. Wild in 2005 describes
the combination of all life-course chemical exposures and body
responses [8,9]. As the exposome is a matter of high inter- and
intra-individual variability [10], developing reliable measurement
tools to map the full spectrum of human exposures is challenging.
The recent advances in statistics, bioinformatics and analytics can
face the new challenges arising within the Exposome research field.
With regard to the chemical composition of the exposome, the use
of latest generation high-resolution mass spectrometry (HRMS)
techniques [11], which have outstanding properties, such as high
mass accuracy, mass-resolving power > 30,000 (R, defined at full
width at half maximum, FWHM), high scan speed and broad dy-
namic range [12], represents the main advance to address this
challenge. Coupled to a separation technique, such as liquid and/or
gas chromatography (LC and GC), HRMS has been successfully
applied for the detection, annotation and identification of new
chemicals in different fields, including forensic toxicology [13,14],
water quality monitoring [15], food safety [16], environmental
toxicology [17] and human exposure to environmental contami-
nants [18]. However, the study of the Exposome requires the
development and establishment of a comprehensive list of chem-
icals or biomarkers to be investigated in population studies and
human biomonitoring campaigns. It is assumed that a large num-
ber of chemicals present in the environment remain unknown to
the scientific community, or the information related to their iden-
tity and physicochemical properties is limited [19]. These chemicals
of emerging concern (CECs) are suspected to exhibit adverse health
effects in humans [20].
Although the analytical workflow for non-target methods de-
pends on several factors, such as the aim of the study, groups of
CECs to be investigated or type of matrix, there is a general scheme
to perform sample analysis and identification of compounds.
Analytical steps, including sample preparation, separation and
detection of CECs should strike a balance between reducing the
potential matrix effects and extracting analytes with a wide range
of chemical properties. Sample preparation and data acquisition
applied in non-target methodologies are basically independent of
the subsequent data analysis approaches. However, once the sam-
ples have been analysed and based on the available information
about the groups of CECs included in the research hypothesis, these
data mining approaches can be divided into suspect screening for2
known-unknowns and non-target screening for unknown-unknowns
[21].
The suspect screening approach aims to identify known-un-
knowns (“suspects”) which are compounds expected to be present in
the sample. For these compounds available information, usually
only chemical name and formula, is limited and no analytical
standards are accessible. In most cases, observed features are
compared against lists of potential candidate compounds (only
name and formula) or libraries (MS or MS/MS spectra) with the
help of data processing software. The aim of non-target screening is
the holistic and all-encompassing coverage of chemical space
through structural elucidation of compounds without any prior
information (unknown-unknowns) [22]. This process should be
supported by the analyst's strong knowledge of chemistry and by
using advanced data acquisition and processing approaches,
together with bioinformatics and modelling tools [21e23].
The development of analytical approaches for non-target
methods to reflect the global risk of simultaneous exposure to the
wide variety of chemicals present in the environment is chal-
lenging, in particular for the identification of the diverse groups of
CECs in human matrices (e.g. urine, blood, serum, placenta and
adipose tissue). The major analytical challenges for human expo-
sure assessment include: i) expected concentrations of CECs and
their biotransformation products are low (below ng/mL level) and
might vary by orders of magnitude between compounds groups
and samples; ii) CECs typically present themselves at lower con-
centration levels than endogenous compounds CECs that might
interfere and suppress detection; iii) high intra and inter-individual
variabilities exist, i.e. sample composition affected by the sampling
time and sampled individual conditions; vi) spectral databases are
incomplete, culminating with a lack of MS/MS spectra and scarce
coverage of metabolites to facilitate structural identification [24];
and v) establishment of a cause e effect relationship between
chemical exposure and health effects is difficult [10,25,26]. As such,
there is an urgent need to develop new wide scope analytical ap-
proaches able to detect, annotate and identify the diverse groups of
CECs currently present in humans and to provide accurate and
reproducible results, for further adequate exposure assessment.
The lack of standardisation for non-target approaches, in terms
of analytical methods, method performance assessment, and result
reporting, is a sensitive topic within the scientific community
[27e29]. Two fields in which progress has been made are metab-
olomics [30,31] and the identification of CECs in environmental
samples [32]. As such, the elaboration of akin harmonisation
guidelines is also needed for the identification of CECs in human
matrices [18,33]. For this reason, several worldwide initiatives have
been launched to address this harmonisation issue of the identifi-
cation of CECs in human matrices by non-target approaches.
The United States Environmental Protection Agency (USEPA) has
led a collaborative trial on non-target analysis (ENTACT) [34] that
involved international both private and public laboratories and was
supported by EPA's ToxCast [35] and ExpoCast programs [36]. The
results of the trial, which was based on the analysis of mixtures of
ToxCast chemicals, pointed out the lack of accuracy, precision, and
reproducibility of the reported identified compounds across
analytical platforms and laboratories [37]. In a European context,
the Network of Reference Laboratories for Monitoring and Bio-
monitoring of Emerging Pollutants (NORMAN) aims to promote
communication and information exchange on CECs between
research teams from different countries through the validation and
harmonisation of non-target methods and data-analysis tools
[38,39]. The network has organised several collaborative trials to
harmonise CECs detection in environmental and biological samples
[32,40e42].
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started in 2017, aims at the coordination, advancement and har-
monisation of EU human biomonitoring programs to provide a
realistic assessment of the current exposure of European citizens to
chemicals and the resulting risks for human health [43]. Significant
advances have been achieved in the HBM4EU project with regards
to the harmonisation of analytical workflows for CECs in human
matrices by non-target approaches [21] and acquisition of MS/MS
spectral libraries [22].
To ensure harmonisation of non-target results for reliable
identification of CECs in human samples, a set of QA/QC measures
covering entire analytical workflows is needed (sample collection,
sample preparation, acquisition and data processing) [33,44].
However, to date, sample preparation has been neglected, despite it
is key stage to achieve real harmonisation of non-target methods
for CECs in human matrices.
Within the HBM4EU project, the main principles and challenges
of the harmonisation in non-target approaches specifically applied
to CEC detection in human matrices have been thoroughly dis-
cussed [21]. Besides, QA/QC measures have been developed for
spectral library compilation using liquid chromatography coupled
to HRMS [22]. This paper aims to propose a set of QA/QC measures
for the harmonisation of non-target methodologies for the detec-
tion of CECs, for the metrological traceability of results [45e47];
and to complement the previous work presented by the HBM4EU
project (Fig. 1). This paper presents a set of QA/QC actions for
covering the analytical workflow stages of sample collection (pre-
analytical actions), sample preparation and (partially) acquisition
method, as well as a framework for establishing an analytical per-
formance of the method that allows results comparison between
laboratories in the same research field.2. Survey of QA/QC implementation status for non-target
approaches
The development of a specific set of QA/QCmeasures starts with
identifying both the current situation in the identification of CECs
in biological matrices and the limitations of the main common
analytical workflows. For this purpose, a dedicated questionnaireFig. 1. Analytical stages addressed for the proposal of dedicated QA/QC actions in the contex
human studies. The dashed arrows show those stages or actions from the analytical workfl
3
on QA/QC measures was circulated between five HBM4EU partner
laboratories selected due to their expertise and involvement in
non-target screening in the exposome research field. Respondents
detailed the QA/QC actions that they usually apply for the analytical
stages other than the data analysis. The major findings drawn from
the questionnaires pointing to a current lack of QA/QC measures
and of harmonisation were largely in agreement with the infor-
mation reported in other research fields, such as metabolomics
[48,49] (Table 1):
i) Lack of consistency in the used analytical terminology, unlike
target approaches where well-established analytical terms
are used [50,51], which impedes the comparability and
interpretation of results. Therefore, technical terms and
concepts are defined in this paper for more unified under-
standing of non-target methods. All definitions are drawn
from European legislation [51], international organisations,
such as UNODC and IUPAC [50,52e55]; scientific networks,
like NORMAN, Eurachem and CITAC [56,57], and specialised
literature [22,58e62]. To facilitate the reading of this
manuscript, the complete glossary is presented in the Sup-
plementary Information (SI-1).
ii) Lack of QA/QC actions covering the whole analytical work-
flow and harmonised method performance assessment.
iii) Undefined criteria for the selection of type (isotopic labelled
or native compound or both) and number of internal stan-
dards (ISs), even though their use is common.3. Quality assurance & quality control measurements
Although great progress has been made on the implementation
of QA/QC actions for analytical workflows in metabolomics and
environmental fields, there are substantial differences in the non-
target analysis of CECs in human matrices that introduce new
challenges. Thus, an appropriate set of QA/QC measures based on
metrological traceability of results is crucial to understand the
causes of undesirable variations and to be able to reduce them to
the minimum. For appropriate use of the set of QA/QC actions, thet of suspect and non-target screening workflows developed for the detection of CECs in
ow, which may be optional.
Table 1
Overview of the QA/QC actions and analytical performance conducted in serum and urine analysis by non-target approaches based on the questionnaire filled by the five partner laboratories.
Analytical stage QA/QC action Laboratory
























ISs fortified samples before extraction (%) 100 - 100 100 100
ISs fortified samples after extraction (%) 100 - - - 100
Procedural blanks (%)
(name used by the laboratory)




Analysis of sample by duplicate - -
Pooled QCs samples
(name used by the laboratory)
(sample
blank)
CRM QCs samples - - - -
LC-HRMS(MS) analysis Solvent blanks -
ISs solution (RT shift & mass accuracy) - -
Signal normalisation (ISs) - -
Samples reinjection
Randomised batch run - -
Daily system check calibration
Analytical performance Calculation of recovery (ISs) -
Calculation of selectivity (ISs) - -
a
-
Calculation of reproducibility (ISs)
a
-
Calculation of repeatability (ISs) -
a a
- -
Calculation of stability (ISs) - - - - -̶
















Summary of the proposed QA/QC measures for each analytical stage of suspect and non-target methodologies used for the CECs analysis in human studies covered in this article.
QA/QC measures Optimisation Analytical parameter evaluated
Sample collection Selection of the sampling material
Define a minimum set of data
Field blanks: assessment of external and pre-
analytical contamination
QC-pooled sample production
Fortified samples with ISs: assessment of CECs
stability/degradation
Fortified samples with parent/metabolite
compounds: assessment of post-sampling (bio)
transformation of CECs
Testing the sampling material
Use SOPs and training
Stability of the analyte




Procedural blank: assessment of external
procedural contamination
Fortified pooled sample with ISs
Fortified synthetic matrix samples with ISs
(optional)
Subsample representativeness
Detection frequency of ISs
Total number of detected features




Procedural blank: assessment of external
procedural contamination
QC samples (CRMs, pooled samples)
Fortified pooled sample with ISs before
clean-up and extraction
Fortified pooled sample with ISs before
instrumental analysis
QC samples (CRMs, laboratory reference
samples)




Extraction efficiency and variability
Extraction efficiency, reproducibility and
SSE(%) between batches
LC-HRMS method Periodical system calibration
Solvent blank: assessment of procedural
contamination and carry-over




ISs solution: mobile phase composition,
elution program, analytical column,
number and speed of scans and dynamic
range
Fortified pooled sample with ISs:




Chromatographic resolution and peak
shape
Total number of detected features





Control chart: faster control over the process
Use of high purity chemicals
Exhaustive cleaning of labware
Written SOPs and training
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mentation and assessment of each individual QA/QC action,
describing the parameter under evaluation, as well as defining how
these parameters can be influenced. The parameter evaluated for
each QA/QC action and its optimal and decision value should be
previously established by the analyst taking into account the spe-
cific requirement of the study (i.e. goals, number of samples, matrix
and expected compounds) [63]. While the implementation of all
QA/QC actions proposed is not a requirement and depends on the
project's goals, the adoption of dedicated actions for each analytical
stage is necessary to ensure reliable results. Table 2 summarises the
proposed measures.3.1. Internal standards
Either analytical standards of native compounds not expected to
be present in the matrix or isotopically labelled compounds can be
used as internal standards (ISs). Due to the difficulty of finding
compounds that are always absent in human matrices, the use of
isotopically labelled ISs for assessing method capability is more
advantageous. Since they normally do not occur in nature, they can
be distinguished from the matrix components. For more effective
utilisation of ISs as part of the QA/QC strategy, it is crucial to select
the appropriate compounds according to both the research goals
and data processing strategy. As a general rule, and where possible,
the selection of compounds as ISs should be governed by the
following criteria:
i) Chemical structure similarity. Ideally, ISs are structurally
identical to the compounds to be determined, in order to
ensure the same analytical behaviour and response. When
suspect screening is performed, the ISs should be represen-
tative of the compounds classes of CECs expected (i.e.
screened) in the samples. For non-target screening analysis,
the selection of ISs presents an even greater challenge. Due to
the intrinsic lack of chemical information of non-target
methodologies, this is difficult or even impossible to ach-
ieve. Thus, the purpose leading the ISs selection should be to
strike a balance between available chemical information,
compound representativeness, matrix components infor-
mation and project's aims. A smart strategy is selecting a set
of ISs based on the data processing approach (e.g. chemicals
with halogens, hydrophobicity, bioavailability) and the aims
of the project (e.g. pharmaceuticals, legal pesticides).
ii) Chemical properties. The selected ISs should cover a wide
range of physicochemical properties, such as the octanol/
water partition coefficient (logKow), molecular weight and
acid dissociation constant (pKa). In addition, compounds
whose hydrolysis rate constants are well-known or have
been empirically calculated should be included as well, in
order to be able to assess potential degradation processes.
iii) Type of species. CECs and/or their transformation products, as
well as typical humanmetabolite-types (e.g. glucuronidated-
type for urine matrix) should be represented in the ISs
selection.
iv) Commercial availability. Because of requirements of project
aims (e.g. occupational exposure studies), the use of specific
compound as ISs might be preferred. However, since most of
the CECs and/or their metabolites are unknown compounds,
it can be difficult or even impossible to obtain analytical
standards, in particular isotopic labelled ones, from com-
mercial suppliers. Custom synthesis might be an option, but
other factors, such as cost, time, and number of needed ISs
can make it unfeasible.6
The number of used ISs depends on the aims and individual
attributes of each study. A too small number of ISs does not justify
their usefulness, while a large number of ISs may hamper the CECs
detection and the evaluation of both analytical method and
decision-making process (i.e. acceptable/non-acceptable analytical
performance results). A smart strategy is having at least one ISs per
expected compound group (i.e. food additives, pharmaceuticals,
personal care products/cosmetics, plasticisers, pesticides, etc.),
including ISs structurally characteristic (e.g. halogen atoms, aro-
matic groups), and ensuring that their respective elution times
span the whole chromatogram or retention time window of
interest.
3.2. Sample collection
The implementation of a QA/QC set for sampling may be
complicated, because many matrices are collected by healthcare
professionals (e.g. blood, plasma, serum, adipose tissue and
placenta). The potential systematic error can be reduced by
developing detailed standard operational protocols (SOPs) for
sampling and storage, and training anyone who performs the
sampling. Depending on the type of human matrix, the sample
collection varies from single-step to multiple-stages. Subsequently,
a risk exists that some of the identified and reported chemicals in
samples actually originate from the sample collection procedure
(background contamination). Furthermore, the ratio between the
parent compounds and their metabolites may change over time
because the sample stability could become compromised. Thus, the
following dedicated QA/QC actions for sampling are proposed:
i) Sample information. Criteria for acceptance/rejection of
samples when samples arrive at the lab should be defined.
Only samples with guaranteed traceability of the whole
sampling process and storage may be included in the
considered studies. When samples from biobanks are ana-
lysed the use of project-dedicated QA/QC measures at this
stage is unfeasible, at least information about the performed
sampling process and storage conditions is required (i.e.
when and where samples were collected, how and by whom
that was carried out). In case of new samplings, all samples
should be accompanied by a sampling questionnaire gath-
ering information about the sample, such as the date of
sampling, type (e.g. spot urine sample, first-morning urine,
24 h urine), volume, additives, and any details that could
influence the results of the analysis.
ii) Field blanks should be used to enable the identification then
further exclusion of background chemicals coming from the
sampling material and handling process. Background
contamination originates from both leaching from materials
and preservative addition. Since the leaching of chemicals
depends on the time-of-contact and storage conditions, the
use of field blanks from the beginning of the sampling
campaign is crucial and they must be submitted to equal
processing as samples. A conservative number of field blanks
is about 10% of the total sample number. To obtain field
blanks, collection devices containing a synthetic matrix (e.g.
simulant solution of saliva or urine [64,65]) or solvent are
prepared together with the samples and submitted to the
same procedure (e.g. tubes for collection of blood contain
chemicals for allowing or blocking coagulation process).
Furthermore, field blanks must be stored under the same
conditions as the samples. Since the physicochemical prop-
erties of the matrix may affect both the leaching and
contamination processes, the use of synthetic matrix rather
than solvents is preferable.
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samples with ISs during their collection is to detect potential
losses or degradation issues. However, since humanmatrices
are frequently collected by healthcare professionals, the
implementation of fortified samples at this stage might be
unfeasible. In this case, the samples could be fortified
immediately after sampling, as soon as it can be performed.
In this way, the analyte stability is still (partially) evaluable.
Ideally, all samples should be fortified with ISs, especially
those with well-known hydrolysis rate constants, but the
high costs for wide-population studies make this difficult in
practice. Therefore, the number of fortified samples can be
adjusted based on the goals and cost or even the preparation.
The preparation of a pooled sample made up of an aliquot
from all the samples (QC-pooled sample) at this stage is
strongly advisable, which can be also fortified with ISs. In any
case, fortified samples must be representative of the whole
batch of samples. When the individual fortified samples
approach is performed, one third of the samples is a con-
servative number, but the minimum number of fortified
samples required to obtained representative data about all
the samples can be calculated by applying the following










where D is the margin of error (%), a the significance level, b is the
probability of detecting a significant result, SD is the maximum
standard deviation allowed; and Z-score is the number of standard
deviations a given proportion is away from the mean. For the
Normal distribution, Z-values are 1.96 (a0.05) and 1.28 (b ¼ 90%).
The maximum values of D and SD, and the minimum value of b are
previously defined by the analysts based on their experience, the
project aims and the matrix-type.
iv) Fortify synthetic matrix with analytical standards of parent
compounds and metabolites (QC samples). Since the obtaining
of both blank samples (that means samples without any of
the compound of interest (CECs)) and enough volume/
amount may be unfeasible, the use of a synthetic matrix is
advisable. The synthetic matrix can be either commercially
available (e.g. horse serum) or in-house prepared (e.g. a salt
mixture solution to simulate human saliva [65]). Collection
conditions, such as type or material of devices, storage con-
ditions, and freeze/thaw cycles can modify the parent/
metabolite ratio originally present in the samples. This effect
has been widely studied for plasma and serum in the
metabolomics field [67], and is strongly dependent on the
chemical properties of the matrix (pH, salts, etc.). This action
can be combined with the use of field blanks. Albeit the
number of fortified synthetic matrix QC samples depends on
the intrinsic characteristic of the study, for keeping the
consistency with the use of field blanks, a minimum of 10% of
the total sample number is advisable.3.3. Sample preparation
3.3.1. Sample pre-treatment
A pre-treatment stage, such as homogenisation and deconju-
gation, is frequently performed for the analysis of human samples.
Sample pre-treatment may be crucial and strongly affects the7
outcomes of exposome studies. Thus, in addition to the use of
procedural blanks, the pre-treatment process should be optimised,
and other QA/QC actions should be implemented. Since human
samples are usually limited in volume, a pooled sample prepared
from volunteers or preferably a QC-pooled sample is advisable for
optimisation purposes.
Solid matrices, like adipose tissue, meconium, and placenta are
submitted to particle size reduction and/or homogenisation [18].
Furthermore, in many studies, only a sample portion is analysed, so
subsample representativeness should be studied. Thewhole matrix
should be ideally fortified with ISs before the homogenisation and
partitioning process. After the analysis of the subsamples, the
detection frequency of the ISs and the total number of mass fea-
tures can be used for assessing (optimisation) the process and the
study of representativeness along sample batches.
The need for a deconjugation step in urine is a controversial
topic in the human biomonitoring field of CECs. The advantages and
disadvantages of performing deconjugation in non-target ap-
proaches during CECs determination have been discussed by
Pourchet et al., 2020 [21] and it is not the subject of this paper.
However, when deconjugation takes place, the efficiency and
suitability of the process for a specific metabolite-type can be
studied. Thus, pooled or synthetic matrix samples are fortified with
ISs of conjugated metabolites and submitted to the deconjugation
process. Both the deconjugation and biotransformation process can
be evaluated based on the detection frequency of the ISs-
conjugated/ISs-free, a semi-quantitative approach and the total
number of mass features (to assess the potential contamination
background of this stage). Whether the enzymatic deconjugation
mode is selected, in addition to the reaction conditions, the type
and the number of enzyme units per mass unit and the lot number
should be reported to facilitate batch comparison.
As for the rest of the analytical stages covered in this manu-
script, the decision-making is based on the criteria previously
established and described by the laboratory in charge of the ana-
lyses. So, when the pre-treatment step under optimisation or the
batch sample does not accomplish with optimal or decision values,
it is considered as failed and the analysis should be performed
again.
3.3.2. Clean-up and extraction
Human tissues and biofluids are complex matrices owing to
their composition rich in proteins, lipids and/or salts. An ideal
sample preparation suitable for the CECs detection should be able
to extract a wide range of chemicals and to eliminate potential
matrix effects. Yet in practice, the balance between extraction and
purification is complicated and presents numerous challenges: i)
the wide (unknown) diversity of chemical properties of CECs may
lead to losses of interesting compounds by inappropriate sample
preparation; ii) CECs are present at different concentration levels in
the same sample leading to difficulties to determine them in a
single analysis; iii) some endogenous compounds are typically
present in higher concentrations than CECs and may cause matrix
effects; and iv) some endogenous compounds, such as lipids and
proteins may interfere with the CECs detection in both LC and MS
[21,68e72].
Although relatively simple and consensual sample preparation
has been proposed in other fields such as metabolomics mainly
focused on endogenous markers of effect, the determination of
exogenous markers of chemical exposure or their biotransforma-
tion products (metabolites), typically at trace concentration level,
usually requires more complex methods such as solid-phase
extraction (SPE) and liquid-liquid extraction (LLE), as well as a
thorough sample preparation optimisation. The evaluation of
extraction efficiency and matrix effects are two key factors in this
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be implemented:
i) Sample clean-up method optimisation. Endogenous mole-
cules, such as proteins and lipids, should be removed to
overcome their negative effects on the CECs determination.
The use of organic solvents and acids for protein precipita-
tion is frequently used for bioanalysis. Chemical filtration
(e.g. Captiva® or Isolute®-PDL cartridges) can be used to
specifically eliminate lipids. Clean-up stages should be opti-
mised by using fortified samples with ISs to ensure the non-
exclusion of potential CECs or their chemical stability. For
this purpose, pooled samples are advisable, but naturally
contaminated samples should also be used preferably when
possible.
ii) Extraction method optimisation based on extraction efficiency
and reproducibility. Synthetic matrix samples, pooled sam-
ples, naturally contaminate samples, or even procedural
blanks fortified with ISs can be used for method develop-
ment reducing the inter-variability factor. Based on the
project goals, the optimisation can be performed using a
semi-quantitative or qualitative approach.
iii) Extraction method optimisation based on matrix effects. The
signal suppression or enhancement (SSE) caused by matrix
components can be evaluated by comparing the instru-
mental response obtained for the ISs solution and the same
amount of ISs spiked in a sample after extraction and prior to
LC-HRMS analysis. Equation (2) [73] calculates the percent-
age of matrix effects:
SSEð%Þ¼ Signal of IS in spiked sampleafter extraction
Signal of ISs in standard solution
x100 (2)
A calculated SSE value above 100% represents an enhancement
of the ISs signals, while values below 100% indicate suppression of
the ISs signals. For the identification of CECs, signal suppression
effects could have direct consequences precluding their detection.
Signal enhancement is also an undesirable effect, since it makes
semi-quantitative analysis through normalisation of signals diffi-
cult to perform.
iv) Procedural blanks. During sample preparation, many com-
pounds may be unintentionally introduced into the sample
extract from solvents, labware and/or consumables. Any
instrumental signal in the procedural blanks can be identi-
fied as a contaminant and then submitted to evaluation of
removal from data processing.
v) QC samples. Certified reference materials (CRMs) allow
quality assessment across different laboratories. Certified
reference materials of CECs in human matrices are not
available. However, laboratory reference samples, which are
another type of QC, can be prepared by fortifying pooled
samples with ISs [74,75]. Fortified synthetic matrix samples
and samples previously analysed in other batches may be
also used as QC samples. QC samples should be included in
each sample batch to assess method suitability. After batch
analysis, extraction efficiency, reproducibility and SSE (%) are
calculated for QC samples. If the calculated values for QC
samples fail to comply with the previously defined accep-
tance criteria (i.e. the proposed guideline in this article or the
defined and stablished by the laboratory performing the
analysis), the sample batch needs to be re-submitted to the
analytical process.8
3.4. LC-HRMS analysis
The identification of CECs in human matrices usually requires
the use of high-resolution tandemmass analysers that provide both
full-scan MS and MS/MS [21,22], such as quadrupole-quadrupole
time of flight (QqTOF), ion trap-Orbitrap (LTQ-Orbitrap) and Q-
Exactive Orbitrap (QqOrbitrap). These detectors, combined with LC,
mainly use electrospray ionisation (ESI) owing to its high versa-
tility, albeit atmospheric pressure chemical ionisation (APCI) and
matrix-assisted laser desorption ionisation (MALDI) have also been
applied [18]. Both LC andMSmethods should be optimised to make
a maximal number of potential CECs accessible.
i) LC method optimisation. The development and optimisation of
chromatographic conditions has to consider several factors.
Solvents, pH and buffer concentrationmay directly affect elution
reproducibility and resolving power (e.g. tailing peaks). The
formation of different adducts in the ionisation process (e.g.
typically ammonium, sodium or potassium adducts in the pos-
itive mode) depends strongly on the mobile phase modifiers
selected and may have a significant impact on the CECs identi-
fication capability. On the other hand, the stationary phase,
length, internal diameter, and particle size of the analytical
column determine the efficiency and selectivity of the separa-
tion. For human matrices (e.g. urine), the presence of metabo-
lites, which are usually more polar, can be more important than
of parent compounds. So, other stationary phases than
reversed-phase, such asmodified reverse-phase or HILICmay be
considered. An appropriate IS mixture should be used for testing
(system suitability) and optimising of LC conditions, including
the elution program and injection volume, which should be kept
as general as possible. Once the LC method has been optimised,
the total ion chromatogram (TIC) of a fortified sample should be
visually inspected to check the lack of compound signals at the
solvent front or the end of the chromatogram, as well as to
assess potential retention time shifts between injections.
ii) MS(/MS) method optimisation. An appropriate ISs solution
should be used for HRMS method development based on the
optimisation of mass accuracy, mass resolution, and signal to
noise ratio. For this purpose, parameters such as the number and
speed of scans (MS andMS/MS level) and dynamic range have to
be optimised. On the other hand, after method optimisation,
pooled samples fortified with ISs should be used to assess the
operational concentration range of the method, from the esti-
mated detection limit to the maximum signal to noise ratio
without detector saturation.
A dedicated set of QA/QC is proposed for LC-HRMS acquisition
methods to ensure system suitability, as is the case in other stages
of the analytical procedure (Fig. 1).
i) System calibration. Periodical tune and calibration of the
HRMS instrument should be performed before sample batch
analysis or at least, calibration should be daily checked [22].
ii) Background contamination. System components and mobile
phase solvents can introduce potential contaminants that
belong to chemical groups included in the CECs category.
Thus, it is crucial to detect and minimize them as much as
possible by running solvent blanks within each sample
batch. To set a specific number of required blank solvents is
complex, because factors such as length of the batch (in
terms of numbers of samples but also time duration) or
mobile phase composition can have a major influence. As a
general rule, the optimal number of solvent blanks is which
gives a significant statistical difference on the total of
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house threshold based on the project's aims) [76]. In the
same way, a cleaning procedure should be developed and
applied before and after performing the analyses to avoid any
cross-contamination.
iii) Carry-over. This well-known and undesirable effect should be
investigated and eliminated during acquisition method
development [22,77]. It has been proven that hydro-organic
mobile phase composition is more effective for carry-over
reduction that pure organic compositions [78]. However,
the complexity of human matrices and highly variable
chemical concentrations require the inclusion of solvent
blanks after the analysis of samples in each sample batch for
routine system monitoring of carry-over [48]. To set the
number of solvents blank within a sample batch, similar
criteria as for background contamination assessment can be
followed [76]. On the other hand, the autosampler may be a
source of carry-over in LC-MS, especially in bioanalysis. Thus,
the use of a full loop injection instead of a partial loop might
be of help for the total removal of this undesired effect,
especially in the analysis of complex samples or when a high
concentration of compounds is expected [79]. Besides, the
use of cleaning samples (i.e. water:isopropanol mixture)
along the sample batch reduces or even eliminates the
adverse effects of carry-over [77,78].
iv) Signal variability and retention time shift assessment. Varia-
tions in signal intensity and retention time shifts are usual
phenomena, especially in large-scale experiments caused for
example by the precipitation of matrix components in the
ion source or the column. Sample reinjection allows assess-
ing the instrumental signal variability and retention time
shift within a sample batch. This instrumental evaluation
should be performed both in the absence of matrix (ISs so-
lution) and in the presence of the studied matrix (QCs sam-
ples). When sample reinjection is not feasible (i.e. low
sample volume, low analytes stability), these phenomena
can be evaluated through the monitoring of the ISs and well-
known endogenous compounds signal and retention time in
the samples analysed along the batch. Although this strategy
is suitable for the evaluation of these phenomena, it can be
misleading because more factors are affecting it (e.g.
extraction efficiency, ISs stability).
v) The order solvent blanks injection within a sample batch. Even
in a randomised batch, the order of solvent blanks should be
decided by the analyst based on the research aims,
complexity of matrix, and batch length. As a generalTable 3
Proposed minimum criteria of the performance characteristics for suspect and non-targe
Performance
characteristics




mL1 or ng g1)
As low as possible








As low as possible
Repeatability (RSD
%)
As low as possible
Stability RSD % 40
Representativeness RSD % As low as possible
SSE: signal suppression or enhancement; RSD: relative standard deviation.
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recommendation, solvent blanks (for background contami-
nation and carry over assessment) are analysed at the
beginning and end of the batch, and before and after QC
samples.3.5. Other QA measures
In addition to the above mentioned set of QA/QC measures for
the identification of CECs in human samples, other good practices
can be implemented:
i) System suitability. Regular (preventive) maintenance actions
prevent measurement errors and major instrumental issues
[22]. This general provision indeed appears of even high
importance in the context of sample preparation of low
selectivity typically applied for suspect and non-target
screening methods for which the medium-term stability of
the measurement system may be impaired by a higher
dirtiness of the injected extracts. The daily analysis of the ISs
solution is advisable for checking the system suitability.
ii) Control chart. The use of a graph is an easy way to control
process stability. The lower and upper limit is set for each
variable, so any measure outside from these limits is
considered an outlier and requires an intervention or action.
It is commonly used for QC samples, but it can be useful for
LC-HRMS-MS system suitability as well (tune, calibration,
and pressure profiles) [77].
iii) Use of high purity chemicals. The use of chemicals with high
levels of purity (>95%) and LC-MS grade solvents reduces
potential contamination. As well as, the material-made up
labware should be carefully selected in order to avoid po-
tential contamination (e.g. polysiloxane, silicone, etc.).
iv) Exhaustive cleaning of labware. All the material and labware
used for sample preparation and standards solutions prep-
aration should be submitted to a strict protocol of cleaning
for removal potential background contamination.
v) Standard operational protocol and personnel training. The
development of in-house SOPs significantly reduces bias er-
rors due to slight variations at multiple steps and handling.
The SOP document should provide a complete description of
the QA/QC actions, as well as, the criteria for both the QA/QC
actions and the analytical workflow assessment. Moreover, a
record of lot numbers for the chemicals used with each SOP
facilitates the traceability of the analyses. On the other hand,
training of the staff involved in any of the analytical stage (ift screening of CECs in human biological matrices.
fraction (ng mL1 or ng g1)
1e10 10e100 100e1000 >1000
1 5  one order of
magnitude lower
 one order of
magnitude lower
60e150 50e150 50e150 40e150
40 30 30 20
40 30 15 15
30 25 20 <20
20 15 10 10
40 30 15 15
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the training, should be described in detail in the SOP as well.
Once the SOPs are developed, in order to ensure their correct
interpretation and application, personnel should be trained
by an experienced member of the laboratory.4. Framework for analytical performance reporting
According to the strict IUPAC definition [54,55], the concept of
validation does not apply to non-target approaches, for which
compounds are not preselected or even totally unknown. There-
fore, the different sources of error affecting the analytical perfor-
mance cannot be individually evaluated for them. Nevertheless, as
it has been shown by Simonet [63] themost relevant quality control
actions in quantitative analysis are applicable to non-target meth-
odologies with the appropriate modifications and adaptations. On
these premises, we propose a framework for establishing and
document the analytical method performance. This is a tool for
harmonisation of results based on a wider validation concept to
prove that a method complies with previously established criteria.
The development of this framework, as well as the suggested
limits for each analytical parameter, are based on the existing
validation guidelines for quantitative, qualitative and metab-
olomics analytical methods [31,38,48,50,51,53e55,60,63,80]. The
combined use of ISs and the evaluation of the method potential for
CECs identification with quantitative markers allow the compari-
son of results from different non-target methods, as well as in-
crease the level of confidence for the reported results. While it is
true that analytical performance is estimated only for a group of
representative compounds (ISs), it may explainwhy some expected
compounds in a matrix cannot be detected. Since IS compounds
have been selected according to the intrinsic characteristic of each
project (see Section 3.1.), when samples do not accomplish with
minimum performance characteristics, method optimisation
should be revised and samples re-analysed. The acceptable number
of samples that failed with the criteria should be established and
reported by the analyst on each project. Table 3 shows a proposed
minimum criteria of the performance characteristics based on ISs
response, according to the expected CECs concentrations present in
the sample. Assessing and reporting the application range of a
given method proposed for suspect/non-target screening therefore
appears as an important element of comparability.4.1. Sensitivity. Limit of detection/limit of identification
The CECs can be present at different concentrations depending
on the extent of the exposure and the studied matrix. It is therefore
crucial to define the detection ability of the proposed method. For
this purpose, decreasing ISs concentrations in both solution and
fortified pooled QC samples are analysed. The initial concentration
for the ISs depends on the CECs expected concentration in the
samples (e.g. therapeutic range) either the aims of the research.
Lower amounts of ISs should be analysed until the peak area of at
least one of the IS reaches a signal to noise ratio of 10. The signal to
noise ratio is a key factor for the identification of compounds during
data processing where signal to noise thresholds can be set as filter.
Thus, the method detection ability must be sufficient to later allow
the identification of CECs. It is desirable that the ISs limits of
detection are as low as possible, but in practice the ISs limits of
detection only need to be lower than CECs expected concentration
(limits of identification), in order to enhance the detection and
potential CECs identification (Table 3).104.2. Selectivity
Despite being one of the most important analytical parameters,
selectivity is not commonly evaluated in non-target approaches
[81]. Due to the complexity of human matrices, both matrix effects
and interferences are common undesirable issues in bioanalysis
that affect the selectivity [54]. It is not possible to evaluate the
specificity for all compounds due to practical limitations, but the
method selectivity for the ISs can be assessed. According to the
selectivity definition, it can be calculated through two different
approaches, matrix effects and interference effects.
The measurement of the matrix effect for ISs through the
calculation of SSE (%) (see Section “3.3.2 Sample clean-up and
extraction”) gives an estimate of the influence that the matrix
componentsmay have on the CECs present in the sample, under the
analysis conditions. To overcome this negative effect on the CECs
identification, the lowest acceptable SSE (%) value for the ISs at
representative concentration is 40% (Table 3). Although this value is
lower than the accepted range for target bioanalytical methods, it
may still be considered a restricting limit for a non-quantitative
method. This value has been proposed as a result of considering
the combined effect of (potentially) low recoveries (even so low as
20%) and measurement variability, that could negatively affect the
identification procedure. While an upper limit does not seem
necessary for identification purposes, it is important to consider
that the signal enhancement may hamper any semi-quantitation
based on signal normalisation. Therefore, a general upper limit of
150% is proposed, which is based on the combination of measure-
ment variability (up to 30e40%), and the recovery error allowed for
target methods in bioanalysis (þ10e20%) [50,51]. The matrix effect
evaluation for all samples is strongly advisable, but for harmo-
nisation purposes, reporting matrix effects for QC samples is
adequate, too.
The evaluation of potential interferences in the samples can be
accomplished by analysing blank samples or samples fortified with
ISs [80]. Once the samples have been analysed, data processing is
performed and checked for false and true positive identifications,
respectively. The use of fortified samples is preferable over blanks
because it gives a more realistic approximation of the existence of
interference [80]. Since an interference can be systematically pre-
sent in the matrix or be specimen-dependent, it is advisable to
evaluate this effect for all analysed samples. However, in large
batches, it can be unfeasible for practical reasons. In such a case, the
analysis of fortified QC pooled samples is a smart strategy. Once the
samples have been analysed, data processing is performed and the
number of true and false positive identifications is calculated for
the spiked compounds. Ideally, no false positive identifications
occur and all ISs are truly identified. However, a small margin of
error can be tolerable, albeit the acceptance criteria of true and false
positive ratio should be pre-established by the laboratory in charge
of the analysis and subsequently reported with the results.
4.3. Accuracy
As previously defined (see “SI-1-Harmonised definitions1”),
accuracy may be described by both trueness (recovery when a
suitable certified reference material is not available) and precision.
To evaluate the extraction efficiency of the method (recovery), at
least six pooled QC samples fortified with ISs at a relevant con-
centration according to the expected CECs concentration range
should be analysed within the same batch. Since recovery and
precision can strongly affect the CECs identification, both parame-
ters should be evaluated as a whole. Acceptable lower limits for
recovery according to the concentration range are given in Table 3.
Although an extraction efficiency of 20% is commonly accepted in
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advisable and in any case, it must be higher to precision values.
Precision can be evaluated in terms of reproducibility (intra-day
precision) and repeatability (inter-day precision) and is usually
expressed as the relative standard deviation (RSD) or the coefficient
of variance (CV). In non-target methods, the linearity between the
analyte area and concentration is often not addressed. This may
introduce an error in the precision evaluation. Thus, the substitu-
tion of SD of the ISs area by median absolute deviation (MAD) is
strongly advisable [48]. The reproducibility can be addressed by
analysing at least six QC samples spiked with ISs at a representative
concentration within the same batch. The QC sample must be
simultaneously treated with the samples and under the same
conditions by the same operator. To evaluate the repeatability, the
procedure must be repeated on three different days. Both repro-
ducibility and repeatability are calculated according to the




where 1.4826 is the scaling factor described by Hoaglin et al. [82].
The RSD tolerance range under reproducibility and repeatability
varies with the concentration, as shown in Table 3.
4.4. Stability
Due to the general chromatographic conditions, non-target
acquisition methods often tend to have a long run time. Further-
more, many QA/QC samples (i.e. ISs solution, solvent blanks, rein-
jected samples, QC samples, etc.) are included in the batch, which
increases the analysis time. Furthermore, the batch should be
analysed twice, for positive and negative polarity, thus the batches
run often entails several days, depending on its length. Therefore,
the stability of the sample extracts in the autosampler should be
ensured, at least until the end of the batch analyses. For this pur-
pose, both the ISs solution and a QC pooled sample fortifiedwith ISs
should be reinjected by duplicate at least three times along the
same batch of samples (at the start, middle and end of the batch).
Stability can be evaluated through two different approaches: i)
qualitative, by comparing the entire number of detected features in
three replicates; and ii) semi-quantitative by calculating RSD for ISs
areas according to Eq (3). Since the number of detected features is
affected by the variability of the instrumental measurement, this
factor needs to be considered during the comparison. The calcu-
lated RSD of ISs for stability should always be lower than the re-
ported reproducibility for the same batch, or method repeatability
when it was not possible for the same ISs, and in agreement with
the criteria presented in Table 3.
4.5. Representativeness
To evaluate the representativeness of the subsample size used in
the analysis of a solid matrix, the mean RSD obtained for the
measurement of the ISs area in the QC samples individually forti-
fied (at least 6 samples) is compared against the mean RSD ob-
tained from themeasurement of QC subsamples taken from a larger
pooled QC sample fortified at the same concentration. The calcu-
lated RSD (Eq. (3)) has to agree with the reproducibility of the
method (Table 3). When the characteristics of the matrix (i.e. nails
or meconium) hinder its homogenisation, the sample representa-
tiveness can be addressed through the comparison of the variances
by applying the Fisher test. Though it is stricter than the RSD
method, the Fisher test gives specific information about the sig-
nificance of the association between both sets of subsamples [83].115. Interlaboratory comparability investigation
Up to now, there are no standardised analytical methods for CECs
determination and identification in human matrices. Due to the
importance of accuracy and comparability of the reported results,
especially in large-scale projects where samples are analysed by
different laboratories, an interlaboratory comparability investigation
(ICI) is stronglyadvisable. Although there are several guidelines on the
ICI criteria (i.e. ISO-17043-2010 [84], EUROCHEM-2012 [85]), these are
dedicated to quantitative analytical methods (target approach). For
non-target methodologies (qualitative) different criteria and good
practices covering several aspects of the methods by organising
interlaboratory trials have been proposed [28,34,37,63]. When the
comparability of different analytical workflows and subsequently
produced data appears as a major objective, then this interlaboratory
process has to be promoted. Defining a common set of QA/QC refer-
ence compounds and assessing the individual method's capacity to
effectively detect and identify those QA/QC markers at a given con-
centration level can be proposed as a general procedure.
6. Conclusions
A set of QA/QC measures for sample collection (pre-analytical ac-
tions), sample preparation and the acquisition method (partially) has
been proposed. These actions can be applied entirely or partially.
However, all analytical stages should be covered to ensure the
required quality of the results for Exposome research. A detailed SOP
of the analytical method, including all QA/QC measures and the
evaluation criteria, themetadata (i.e.materials and reagents, listof ISs,
a description of what is to be measured, how this is to be carried out,
etc.), together with the obtained results should be reported, since all
these parameters can significantly affect the CECs determination,
identification and the results’ comparison.
Also, for thefirst time a framework for the assessment of analytical
method performance in the identification of CECs in human samples
has been developed and presented for non-target approaches. This
framework is an objective and reliable tool formethod harmonisation
towards the comparison of results obtained by different laboratories.
Whilst more effort from the scientific community is needed to reach
the same level of standardisation for the determination of CECs by
non-target methods as in target bioanalysis, the current set of QA/QC
measures in the frame of the HBM4EU initiative is a valuable starting
point for dealing with this challenging topic.
The Exposome research field is very promising, but challenging.
The amount and variety of chemicals in the environment to which
humans are exposed, is experiencing continuous growth. Thus,
Exposome needs analytical strategies to obtain a holistic view of
external (non-genetic) factors affecting human health, through high
quality and comparable results. The development of dedicated QA/QC
actions for the determination of CECs in humanmatrices contributes
greatly to the achievement of these objectives. From an analytical
point of view, some challenges need to be addressed, such as
increasing the capability for exogenous chemicals screening in
humans, which also requires the achievement of the same harmo-
nisation degree in non-target methodologies as for target analyses.
Consequently, future efforts must be directed to ensure the quality of
the results and protection against false negative/positive compounds
detection. Thus,deeper research in termsofQA/QCandharmonisation
through theorganizationof collaborative trials at theEuropeanand/or
international levelmayallow the establishmentof stricter andprecise
QA/QC actions and specific minimum criteria of the performance
characteristics for suspect and non-target screening of CECs inhuman
biological matrices. Moreover, development necessity of comple-
mentary QA/QC guidelines that fully cover the acquisition method,
data-processing and results’ reporting has to be more specifically
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environment or food safety. Networks including experts in theory,
medicine and toxicology must be established in order to elucidate
CECs biological consequences on humans.
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